Apostolos Gaitanidis1,2, Douglas Wiseman1, Mustapha El Lakis3, Naris Nilubol1, Electron Kebebew4, Dhaval Patel1,5. 1. Surgical Oncology Program, National Cancer Institute, Bethesda, Maryland. 2. Department of Surgery, Democritus University of Thrace Medical School, Alexandroupoli, Greece. 3. Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania. 4. Department of Surgery, Stanford University School of Medicine, Stanford, California. 5. Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin.
Abstract
BACKGROUND: Recurrent adrenocortical carcinoma (ACC) has a poor prognosis with minimal clinical and biochemical factors to guide management. The aim of this study was to evaluate the prognostic significance of systemic inflammatory response in patients with recurrent ACC. METHODS: Patients who underwent resection for recurrent ACC were retrospectively analyzed. Preoperative neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio (LMR), and mean platelet volume were calculated. RESULTS: Twenty-five patients (age at operation 52.2 ± 9.5 years) were identified. We observed a statistically significant shorter disease-specific survival (DSS) in patients with LMR less than 4 (41 ± 7.4 months vs 71 ± 12.3, P = .023) and male sex (26.6 ± 4.2 months vs 57.6 ± 9.5 months, P = .079), while time-to-recurrence (TTR) less than 12 months (40 ± 7.7 months vs 70.3 ± 13.1 months, P = .059) had a trend on univariate analysis for worse DSS. On multivariable analysis, LMR < 4 (hazard ratio [HR] 4.18; 95% confidence interval [CI]: 1.18-14.76; P = .027) and TTR less than 12 months (HR 2.77 95% CI: 1-7.62; P = .049) were found to be significantly associated with worse DSS. CONCLUSION: Preoperative LMR greater than 4 and TTR greater than 12 months are associated with longer DSS. Patients with LMR greater than 4 and TTR greater than 12 months may benefit from a more aggressive therapeutic approach and may require less frequent surveillance. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.
BACKGROUND: Recurrent adrenocortical carcinoma (ACC) has a poor prognosis with minimal clinical and biochemical factors to guide management. The aim of this study was to evaluate the prognostic significance of systemic inflammatory response in patients with recurrent ACC. METHODS: Patients who underwent resection for recurrent ACC were retrospectively analyzed. Preoperative neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio (LMR), and mean platelet volume were calculated. RESULTS: Twenty-five patients (age at operation 52.2 ± 9.5 years) were identified. We observed a statistically significant shorter disease-specific survival (DSS) in patients with LMR less than 4 (41 ± 7.4 months vs 71 ± 12.3, P = .023) and male sex (26.6 ± 4.2 months vs 57.6 ± 9.5 months, P = .079), while time-to-recurrence (TTR) less than 12 months (40 ± 7.7 months vs 70.3 ± 13.1 months, P = .059) had a trend on univariate analysis for worse DSS. On multivariable analysis, LMR < 4 (hazard ratio [HR] 4.18; 95% confidence interval [CI]: 1.18-14.76; P = .027) and TTR less than 12 months (HR 2.77 95% CI: 1-7.62; P = .049) were found to be significantly associated with worse DSS. CONCLUSION: Preoperative LMR greater than 4 and TTR greater than 12 months are associated with longer DSS. Patients with LMR greater than 4 and TTR greater than 12 months may benefit from a more aggressive therapeutic approach and may require less frequent surveillance. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Alexander Stojadinovic; Ronald A Ghossein; Axel Hoos; Aviram Nissan; David Marshall; Maria Dudas; Carlos Cordon-Cardo; David P Jaques; Murray F Brennan Journal: J Clin Oncol Date: 2002-02-15 Impact factor: 44.544
Authors: Ilknur Erdogan; Timo Deutschbein; Christian Jurowich; Matthias Kroiss; Christina Ronchi; Marcus Quinkler; Jens Waldmann; Holger S Willenberg; Felix Beuschlein; Christian Fottner; Silke Klose; Anke Heidemeier; David Brix; Wiebke Fenske; Stefanie Hahner; Joachim Reibetanz; Bruno Allolio; Martin Fassnacht Journal: J Clin Endocrinol Metab Date: 2012-11-12 Impact factor: 5.958
Authors: Pedro Marques; Friso de Vries; Olaf M Dekkers; Márta Korbonits; Nienke R Biermasz; Alberto M Pereira Journal: J Clin Endocrinol Metab Date: 2021-09-27 Impact factor: 5.958